Off

Quanterix Simoa Success Grant Proposal 2

Infectious Disease/Immunology Assay Development Award

Infectious Disease

Rules and Regulations

    Quanterix’ unique homebrew ultrasensitive assay development capabilities provide the flexibility for researchers to develop singleplex and multiplex custom Simoa assays.

    Quanterix announces the Simoa Success Grant Program in support of investigators based in the United States who are studying critical topics at the intersection of laboratory and clinical research in Infectious Diseases and Immunology to introduce them to the benefits of Simoa assays for protein biomarker analysis.

    Applicants are encouraged to present a plan for development of a novel Simoa assay utilizing the Quanterix SP-X platform and “Homebrew” assay kit. SP-X homebrew assays follow a sandwich ELISA format and require two target-specific antibodies, recognizing different epitopes. Assay development will also require a positive control sample, such as recombinant target protein, that can be diluted to generate a calibration curve. Preferred projects will address a need for high-sensitivity/specificity protein detection supporting diagnosis, prognosis, or treatment efficacy/kinetics/safety studies for diseases engaging the immune system. Analysis of up to 60 unique samples to show utility of the novel assay for a specific application may be included as part of the proposal.

    A Quanterix designated review committee, including external reviewers, will select winning proposals for up to two awards based upon the novelty, feasibility, merit, and relevance to further work of the proposed assay. Recipients will be invited to present the results from the grant awarded work at Simoa Success Seminars in the fall of 2020, several locations to be determined.

    All Applicants not selected for an award will receive a 20% discount offer that may be used toward purchase of Quanterix products or services related to the proposed study should they decide to continue with their proposed study. This offer will be valid for 6 months from the date of the announced winners.

Simoa Success Assay Development Awards

    Up to two awards will be granted to perform the following services at Quanterix headquarters:
    -Generation of 2 tagged capture antibody reagents
    -Generation of 2 biotinylated detector antibody reagents
    -Initial testing of antibody pair with capture/detector antibody swap against a calibrator curve and specified sample matrix
    -Diluent optimization to maximize signal to noise and recovery of analyte spiked into matrix
    -Calibrator range optimization
    -Sample testing (up to 60 unique samples to be tested in duplicate at one dilution level)

    If selected for an assay development grant, the awardee will be responsible for appropriate packing and shipping of reagents including two analyte-specific antibodies and recombinant analyte (or another type of positive control for calibration) within 1 month of award notification. A minimum of 500 ug of each antibody and 10 ug of recombinant analyte must be provided.

    All samples for analysis must be collected and stored by the applicant’s laboratory and must be compatible for handling in a BL2 facility. Assay development and sample processing timelines will be communicated upon sample receipt.

Eligibility

    Only applicants who do not currently own or have regular access to a Simoa platform and do not currently have studies in progress with Quanterix Accelerator Services are eligible for a grant.

    Candidates for a Simoa Success Grant must be affiliated with an appropriate institution/laboratory in the United States having the physical and economic means to perform the necessary sample collection and any additional analysis proposed. Applicants must be or must show evidence of support by a faculty member or a director of a budgeted research program within a private or public company/institution.

    Awardees must be free to share information/data generated through the grant award with Quanterix. Quanterix reserves the right to review any manuscripts containing data generated through the award prior to submission for publication in peer review journals. Authors will be expected to keep Quanterix informed regarding editing, resubmission, and acceptance of such manuscripts and to support promotion of such manuscripts through Quanterix sponsored media.

    Applicants must agree to allow Quanterix to reference the names of applicants and their affiliated institutions in a public announcement upon selection of winning grants.

    Results and data generated through the grant award that will not be used for publication in a peer reviewed journal must be available for use by Quanterix. Examples of ways that Quanterix may share the data include but are not limited to: 1) white papers or conference posters jointly authored by the awardee and Quanterix scientists 2) presentations to prospective customers interested in similar types of studies.

Application Deadline

    Grant applications must be submitted by 5 p.m. EST on June 1, 2020. Candidates will be notified by June 15, 2020 if their application has been selected for a Quanterix Simoa Success award.

General

    Quanterix’ unique homebrew ultrasensitive assay development capabilities provide the flexibility for researchers to develop singleplex and multiplex custom Simoa assays.

    Grant awardees are solely responsible for all local, state and federal taxes, title, transfer fees, license duties, insurance and all expenses incurred due to the grant. The awardees understand, acknowledge, and agree that the winners are receiving a grant and will hereby release and discharge Quanterix, its employees, agents, officers, directors and legal representatives and assigns from any and all claims, liabilities, damages, losses or expenses arising from or caused by the grant, including, but not limited to the payment of any and all taxes that are due.

Access the Application

Please submit the completed grant application to SimoaGrant@quanterix.com by 5 p.m. EST on June 1, 2020.

Decision of the judges is final. Terms and conditions are subject to change without notice. Void where prohibited by law.